Biomarkers and community-acquired pneumonia: Tailoring management with biological data

Seminars in Respiratory and Critical Care Medicine

Volumn 33, Issue 3, 2012, Pages 266-271

  Torres, Antoni ^a   Ramirez, Paula ^b   Montull, Beatriz ^b   Menéndez, Rosario ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

cytokine; diagnosis; treatment

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COPEPTIN; PROADRENOMEDULLIN; PROCALCITONIN; VASOPRESSIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CAUSE OF DEATH; COMMUNITY ACQUIRED PNEUMONIA; CRB 65; CURB 65; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG TREATMENT FAILURE; HOSPITAL PATIENT; HUMAN; IMMUNE RESPONSE; MORTALITY; PNEUMONIA SEVERITY INDEX; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TREATMENT RESPONSE; VIRUS INFECTION;

ADRENOMEDULLIN; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; CYTOKINES; HUMANS; INFLAMMATION; PNEUMONIA; PROGNOSIS; PROTEIN PRECURSORS; VASOPRESSINS;

EID: 84862495531     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0032-1315638     Document Type: Article

References (45)

1. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA: 1999; 281 1 61 66 (Pubitemid 29025101)
2. Kaplan V, Angus DC, Griffin MF, Clermont G, Scott Watson R, Linde-Zwirble WT. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med: 2002; 165 6 766 772 (Pubitemid 34229645)
3. Deng JC, Standiford TJ. The systemic response to lung infection. Clin Chest Med: 2005; 26 1 1 9 (Pubitemid 40410697)
4. Müller B, Süess E, Schuetz P., et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med: 2006; 260 6 568 576 (Pubitemid 44772377)
5. Masiá M, Papassotiriou J, Morgenthaler NG, Hernández I, Shum C, Gutiérrez F. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem: 2007; 53 12 2193 2201 (Pubitemid 350197304)
6. Müller B, Morgenthaler N, Stolz D., et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest: 2007; 37 2 145 152 (Pubitemid 46066494)
7. Masiá M, Papassotiriou J, Morgenthaler NG, Hernández I, Shum C, Gutiérrez F. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem: 2007; 53 12 2193 2201 (Pubitemid 350197304)
8. Bijlsma JJ, Burghout P, Kloosterman TG., et al. Development of genomic array footprinting for identification of conditionally essential genes in Streptococcus pneumoniae. Appl Environ Microbiol: 2007; 73 5 1514 1524 (Pubitemid 46417876)
9. Luna CM. C-reactive protein in pneumonia: let me try again. Chest: 2004; 125 4 1192 1195 (Pubitemid 38501327)
10. Gibot S, Cravoisy A, Levy B., et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med: 2004; 350 5 451 458 (Pubitemid 38133765)
11. Almirall J, Bolíbar I, Toran P., et al. Community-Acquired Pneumonia Maresme Study Group. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest: 2004; 125 4 1335 1342 (Pubitemid 38501347)
12. Flanders SA, Stein J, Shochat G., et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med: 2004; 116 8 529 535 (Pubitemid 38452644)
13. Müller B, Harbarth S, Stolz D., et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis: 2007; 7 10
14. Polzin A, Pletz M, Erbes R., et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J: 2003; 21 6 939 943 (Pubitemid 36675607)
15. Van dM V, Neven AK, Van den Broek PJ., et al. Diagnostic value of C-reactive protein in infections of the lower respiratory tract: systematic review. BMJ: 2005; 331 26
16. Korppi M, Kröger L. C-reactive protein in viral and bacterial respiratory infection in children. Scand J Infect Dis: 1993; 25 2 207 213 (Pubitemid 23149009)
17. Heiskanen-Kosma T, Korppi M. Serum C-reactive protein cannot differentiate bacterial and viral aetiology of community-acquired pneumonia in children in primary healthcare settings. Scand J Infect Dis: 2000; 32 4 399 402 (Pubitemid 30612155)
18. Virkki R, Juven T, Rikalainen H, Svedström E, Mertsola J, Ruuskanen O. Differentiation of bacterial and viral pneumonia in children. Thorax: 2002; 57 5 438 441 (Pubitemid 34494156)
19. Prat C, Domínguez J, Rodrigo C., et al. Procalcitonin, C-reactive protein and leukocyte count in children with lower respiratory tract infection. Pediatr Infect Dis J: 2003; 22 11 963 968
20. Moulin F, Raymond J, Lorrot M., et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child: 2001; 84 4 332 336 (Pubitemid 32328629)
21. Toikka P, Irjala K, Juvén T., et al. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J: 2000; 19 7 598 602 (Pubitemid 30469764)
22. García Vázquez E, Martínez JA, Mensa J., et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J: 2003; 21 4 702 705 (Pubitemid 36432528)
23. Masiá M, Gutiérrez F, Shum C., et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest: 2005; 128 4 2223 2229 (Pubitemid 41507563)
24. Masiá M, Gutiérrez F, Padilla S., et al. Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect: 2007; 13 2 153 161 (Pubitemid 46115655)
25. Prat C, Domínguez J, Andreo F., et al. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect: 2006; 52 3 169 177 (Pubitemid 43286182)
26. Boussekey N, Leroy O, Georges H, Devos P, d'Escrivan T, Guery B. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection: 2005; 33 4 257 263 (Pubitemid 41152186)
27. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection: 2000; 28 2 68 73 (Pubitemid 30189610)
28. Krüger S, Ewig S, Papassotiriou J., et al. CAPNETZ Study Group. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res: 2009; 10 65
29. Nyamande K, Lalloo UG, John M. TB presenting as community-acquired pneumonia in a setting of high TB incidence and high HIV prevalence. Int J Tuberc Lung Dis: 2007; 11 12 1308 1313
30. Christ-Crain M, Stolz D, Bingisser R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med: 2006; 174 1 84 93 (Pubitemid 43955248)
31. Christ-Crain M, Jaccard-Stolz D, Bingisser R., et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet: 2004; 363 9409 600 607 (Pubitemid 38264177)
32. Schuetz PH, Christ-Crain M, Thomann R., et al. ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA: 2009; 302 10 1059 1066
33. Brunkhorst FM, Al-Nawas B, Krummenauer F, Forycki ZF, Shah PM. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect: 2002; 8 2 93 100 (Pubitemid 34993769)
34. Müller F, Christ-Crain M, Bregenzer T., et al. ProHOSP Study Group. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest: 2010; 138 1 121 129
35. Menéndez R, Martínez R, Reyes S., et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax: 2009; 64 7 587 591
36. Krüger S, Ewig S, Marre R., et al. CAPNETZ Study Group. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J: 2008; 31 2 349 355
37. Menéndez R, Martinez R, Reyes S., et al. Stability in community-acquired pneumonia: one step forward with markers? Thorax: 2009; 64 11 987 992
38. Menéndez R, Torres A, Rodríguez de Castro F., et al. Neumofail Group. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis: 2004; 39 12 1783 1790 (Pubitemid 39657257)
39. Menéndez R, Cavalcanti M, Reyes S., et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax: 2008; 63 5 447 452 (Pubitemid 351692355)
40. Ramírez P, Ferrer M, Martí V., et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med: 2011; 39 10 2211 2217
41. Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T.; German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med: 2010; 182 11 1426 1434
42. Guertler C, Wirz B, Christ-Crain M, Zimmerli W, Mueller B, Schuetz P. Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur Respir J: 2011; 37 6 1439 1446
43. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care: 2005; 9 6 R816 R824
44. Christ-Crain M, Morgenthaler NG, Stolz D., et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care: 2006; 10 3 R96
45. Albrich WC, Dusemund F, Rüegger K., et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis: 2011; 11 112